US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Array Digital Infrastructure Inc.

36.85

-1.0500-2.77%

Post-market: 36.850.00000.00%16:57 EDT

Volume:448.12K

Turnover:16.57M

Market Cap:3.18B

PE:5.96

High:38.18

Open:37.58

Low:36.35

Close:37.90

52wk High:60.82

52wk Low:33.71

Shares:86.38M

Float Shares:15.56M

Volume Ratio:1.68

T/O Rate:2.88%

Dividend:- -

Dividend Rate:- -

EPS(TTM):6.19

EPS(LYR):0.5551

ROE:22.68%

ROA:0.02%

PB:2.52

PE(LYR):66.39

Loading ...

Overview Company News Filings

Lynk Pharmaceuticals Announces NDA Acceptance for Zemprocitinib by NMPA

Annovis Announces $10 Million Underwritten Offering of Common Stock and Accompanying Warrants

TDS publishes 2025 annual report after UScellular wireless sale to T-Mobile

Digitus Group Signs Agreement To Acquire Gulfsat Kuwait

Array Digital Infrastructure announces annual shareholder meeting

Array Digital Infrastructure publishes 2025 annual report after wireless divestiture transition

Press Release: AC Immune Announces Amendment to Morphomer (R) Tau License and Collaboration Agreement with Lilly

RBC Capital Keeps Their Buy Rating on Array Digital Infrastructure (AD)

Blockchain Digital Infrastructure FY25 net loss narrows to $0.8 million; revenue falls 19% to $19 million

Press Release: Connect Biopharma Reports 2025 Full-Year Financial Results and Provides Business Update

Annovis Publishes Historical Review of Buntanetap in The Scientist

Should Apogee Therapeutics’ (APGE) Infrequent-Dosing AD Data and $403M Equity Raise Require Investor Action?

Simply Wall St.

Press Release: INmune Bio Inc. Announces 2025 Results and Provides Business Update

Rademikibart Demonstrates Best-in-Class Potential in Phase 3 Atopic Dermatitis Study

Press Release: Neumora Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Nektar announces data from Phase 2b Rezolve-AD, Rezolve-AA studies

Wahaha Temporarily Halts Majority of Production Lines, Including AD Calcium Milk and Nutri-Express

Celldex Presents Positive Data from Phase 2 Chronic Spontaneous Urticaria and Phase 2 Cold Urticaria and Symptomatic Dermographism Studies Demonstrating Rapid, Profound and Durable Improvements in Patient Quality of Life at AAD 2026

Results Presented at 2026 American Academy of Dermatology (AAD) Annual Meeting Provide Additional Support for the Therapeutic Potential of ATI-2138

GMO AD Partners Details Governance Ties to Controlling Shareholder GMO Internet Group

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.imtigers.com/stock/AD/news?page=9"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"AD","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"AD\",,,,,undefined,":{"symbol":"AD","market":"US","secType":"STK","nameCN":"Array Digital Infrastructure Inc.","latestPrice":36.85,"timestamp":1789675200000,"preClose":37.9,"halted":0,"volume":448120,"hourTrading":{"tag":"盘后","latestPrice":36.85,"preClose":36.85,"latestTime":"16:57 EDT","volume":3628,"amount":133691.80000000002,"timestamp":1789678674923,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.027704485488126575,"floatShares":15563300,"shares":86379877,"eps":6.185934,"marketStatus":"Post-Mkt","change":-1.05,"latestTime":"09-17 17:39:08 EDT","open":37.58,"high":38.18,"low":36.35,"amount":16569797.15,"amplitude":0.048285,"askPrice":37.57,"askSize":53,"bidPrice":36.13,"bidSize":55,"shortable":3,"etf":0,"ttmEps":6.185934,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1789689600000},"marketStatusCode":4,"adr":0,"exchange":"NYSE","adjPreClose":37.9,"postHourTrading":{"tag":"盘后","latestPrice":36.85,"preClose":36.85,"latestTime":"16:57 EDT","volume":3628,"amount":133691.80000000002,"timestamp":1789678674923,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.677672,"impliedVol":0.0496,"impliedVolPercentile":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"AD\",,,,,undefined,":{"symbol":"AD","floatShares":15563300,"roa":"0.02%","roe":"22.68%","lyrEps":0.555055,"volumeRatio":1.677672,"shares":86379877,"dividePrice":0,"high":38.18,"amplitude":0.048285,"preClose":37.9,"low":36.35,"week52Low":33.71,"pbRate":"2.52","psRate":"14.91","week52High":60.82,"institutionHeld":0.3358,"latestPrice":36.85,"committee":0.018519,"eps":6.185934,"divideRate":0,"volume":448120,"delay":0,"ttmEps":6.185934,"open":37.58,"prevYearClose":53.62,"prevWeekClose":38.12,"prevMonthClose":36.66,"prevQuarterClose":36.26,"fiveDayClose":38.05,"twentyDayClose":35.29,"sixtyDayClose":37.91,"dividendPayoutRate":40.52599213795753,"dividendGrowthYears":0,"fiveYearAvgDividendRate":0.4274298457535774},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/AD\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-07","symbol":"AD","fiscalQuarterEnding":"2026/06","expectedEps":0.27,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1786075200000,"reportTimeType":"pre","actualEps":0.44},{"date":"2026-06-11","symbol":"AD","amount":11,"announcedDate":"2026-06-01","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-06-11","defaultRemindTime":1781184600000,"name":"Array Digital Infrastructure Inc.","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-06-25","payableDate":"2026-06-11","currency":"USD","dateTimestamp":1781150400000,"payDate":"2026-06-25"},{"market":"US","date":"2026-05-08","symbol":"AD","fiscalQuarterEnding":"2026/03","expectedEps":-0.06,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1778212800000,"reportTimeType":"pre","actualEps":0.42},{"market":"US","date":"2026-02-20","symbol":"AD","fiscalQuarterEnding":"2025/12","expectedEps":0.32,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1771563600000,"reportTimeType":"pre","actualEps":0.48},{"date":"2026-01-23","symbol":"AD","amount":10.25,"announcedDate":"2026-01-13","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-01-23","defaultRemindTime":1769178600000,"name":"Array Digital Infrastructure Inc.","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-02-02","payableDate":"2026-01-23","currency":"USD","dateTimestamp":1769144400000,"payDate":"2026-02-02"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"AD\",market:\"US\",,,undefined,":[{"executeDate":"2025-08-20","recordDate":"2025-08-11","paymentDate":"2025-08-19","value":23,"currency":"USD"},{"executeDate":"2026-01-23","recordDate":"2026-01-23","paymentDate":"2026-02-02","value":10.25,"currency":"USD"},{"executeDate":"2026-06-11","recordDate":"2026-06-11","paymentDate":"2026-06-25","value":11,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"AD\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.2,"buy":0.2,"hold":0.6,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.2,"analysts":5,"updateTime":1786420800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/AD\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"AD","date":"2026-09-16","current":6.096088,"percent":0.296703,"low":-273.92211,"twenty":-174.118653,"median":21.131016,"eighty":259.752096,"high":320.844562,"avg":56.747835,"sd":169.086147,"marketCap":3288796370},"quantilePoints":[{"date":"2025-08-15","current":-273.850129,"twenty":-273.893318,"median":-273.850129,"eighty":-273.612593,"marketCap":6572403103},{"date":"2025-08-22","current":-200.933798,"twenty":-273.763753,"median":-273.490226,"eighty":-228.502362,"marketCap":4822411161},{"date":"2025-08-29","current":-194.49692,"twenty":-273.591,"median":-200.933798,"eighty":-194.626488,"marketCap":4667926077},{"date":"2025-09-05","current":-189.890035,"twenty":-273.511821,"median":-195.360711,"eighty":-192.519268,"marketCap":4557360841},{"date":"2025-09-12","current":-184.671298,"twenty":-272.73443,"median":-194.119011,"eighty":-189.199003,"marketCap":4432111159},{"date":"2025-09-19","current":-175.349555,"twenty":-256.070925,"median":-192.368109,"eighty":-183.778715,"marketCap":4208389313},{"date":"2025-09-26","current":-169.950862,"twenty":-200.271577,"median":-189.74607,"eighty":-179.092649,"marketCap":4078820677},{"date":"2025-10-03","current":-180.892213,"twenty":-197.170296,"median":-184.671298,"eighty":-177.638601,"marketCap":4341413113},{"date":"2025-10-10","current":-180.028422,"twenty":-195.252737,"median":-184.059446,"eighty":-177.861746,"marketCap":4320682131},{"date":"2025-10-17","current":-179.200623,"twenty":-194.756057,"median":-183.555568,"eighty":-177.18511,"marketCap":4300814940},{"date":"2025-10-24","current":-177.581015,"twenty":-194.345757,"median":-180.586287,"eighty":-177.242697,"marketCap":4261944349},{"date":"2025-10-31","current":-176.105372,"twenty":-193.617663,"median":-180.892213,"eighty":-177.242697,"marketCap":4226528922},{"date":"2025-11-07","current":-171.642452,"twenty":-192.972746,"median":-180.010426,"eighty":-176.702827,"marketCap":4119418849},{"date":"2025-11-14","current":241.378582,"twenty":-192.09564,"median":-179.920448,"eighty":-175.407141,"marketCap":3917333000},{"date":"2025-11-21","current":240.473745,"twenty":-190.782619,"median":-179.452562,"eighty":-172.916544,"marketCap":3902648400},{"date":"2025-11-28","current":261.764027,"twenty":-189.890035,"median":-179.056658,"eighty":-170.850644,"marketCap":4248168400},{"date":"2025-12-05","current":265.117247,"twenty":-189.602105,"median":-178.588771,"eighty":240.420519,"marketCap":4302587800},{"date":"2025-12-12","current":265.543053,"twenty":-189.098227,"median":-177.958923,"eighty":244.409875,"marketCap":4309498200},{"date":"2025-12-19","current":274.059166,"twenty":-184.671298,"median":-177.329076,"eighty":249.043083,"marketCap":4447706200},{"date":"2025-12-26","current":286.620433,"twenty":-184.613712,"median":-177.149119,"eighty":260.390804,"marketCap":4651563000},{"date":"2026-01-02","current":285.396241,"twenty":-184.556126,"median":-176.681232,"eighty":261.913059,"marketCap":4631695600},{"date":"2026-01-09","current":277.199482,"twenty":-183.965869,"median":-175.78145,"eighty":263.648217,"marketCap":4498670400},{"date":"2026-01-16","current":297.372025,"twenty":-183.569965,"median":-174.161842,"eighty":266.266922,"marketCap":4826050600},{"date":"2026-01-23","current":320.844562,"twenty":-183.555568,"median":-173.981886,"eighty":271.994008,"marketCap":5206986400},{"date":"2026-01-30","current":252.1834,"twenty":-183.238845,"median":-172.02036,"eighty":268.321434,"marketCap":4092684400},{"date":"2026-02-06","current":257.665648,"twenty":-182.648588,"median":-169.950862,"eighty":267.224985,"marketCap":4181655800},{"date":"2026-02-13","current":269.109175,"twenty":-182.115917,"median":238.717297,"eighty":267.224985,"marketCap":4367372800},{"date":"2026-02-20","current":267.938209,"twenty":-181.48247,"median":240.926164,"eighty":268.704659,"marketCap":4348369200},{"date":"2026-02-27","current":255.643071,"twenty":-181.064971,"median":244.409875,"eighty":267.842403,"marketCap":4148831400},{"date":"2026-03-06","current":262.668864,"twenty":-180.769843,"median":247.365175,"eighty":267.342081,"marketCap":4262853000},{"date":"2026-03-13","current":255.643071,"twenty":-180.229973,"median":249.043083,"eighty":266.671437,"marketCap":4148831400},{"date":"2026-03-20","current":82.941723,"twenty":-180.021224,"median":248.376453,"eighty":265.819826,"marketCap":4043906649},{"date":"2026-03-27","current":82.498564,"twenty":-179.985233,"median":245.210832,"eighty":265.628214,"marketCap":4022299967},{"date":"2026-04-02","current":84.413012,"twenty":-179.95644,"median":244.199544,"eighty":265.543053,"marketCap":4115640834},{"date":"2026-04-10","current":87.513828,"twenty":-179.920448,"median":240.447132,"eighty":265.117247,"marketCap":4266824209},{"date":"2026-04-17","current":87.691125,"twenty":-179.920448,"median":236.588268,"eighty":264.265636,"marketCap":4275468504},{"date":"2026-04-24","current":86.627343,"twenty":-179.596527,"median":87.806368,"eighty":264.052733,"marketCap":4223602732},{"date":"2026-05-01","current":88.098909,"twenty":-179.308596,"median":87.655666,"eighty":263.999507,"marketCap":4295350384},{"date":"2026-05-08","current":87.40745,"twenty":-179.200623,"median":87.575882,"eighty":263.414024,"marketCap":4261637632},{"date":"2026-05-15","current":21.135166,"twenty":-178.912692,"median":87.337865,"eighty":263.147896,"marketCap":4402539647},{"date":"2026-05-22","current":21.338509,"twenty":-178.876701,"median":86.919883,"eighty":263.041444,"marketCap":4444896694},{"date":"2026-05-29","current":21.222313,"twenty":-178.646357,"median":86.396857,"eighty":262.74338,"marketCap":4420692667},{"date":"2026-06-05","current":21.55845,"twenty":-178.444805,"median":85.972934,"eighty":262.32822,"marketCap":4490711460},{"date":"2026-06-12","current":16.645033,"twenty":-178.17847,"median":85.475751,"eighty":262.157897,"marketCap":3467226884},{"date":"2026-06-18","current":16.18855,"twenty":-177.926531,"median":85.370237,"eighty":262.136607,"marketCap":3372139635},{"date":"2026-06-26","current":14.893798,"twenty":-177.667394,"median":85.086615,"eighty":261.913059,"marketCap":3102437619},{"date":"2026-07-02","current":15.151088,"twenty":-177.480239,"median":84.907561,"eighty":261.764027,"marketCap":3156032250},{"date":"2026-07-10","current":14.416565,"twenty":-177.285886,"median":83.339562,"eighty":261.593705,"marketCap":3003028221},{"date":"2026-07-17","current":14.495412,"twenty":-177.192309,"median":82.498564,"eighty":261.253061,"marketCap":3019452383},{"date":"2026-07-24","current":14.184174,"twenty":-177.005154,"median":82.259257,"eighty":261.061448,"marketCap":2954620167},{"date":"2026-07-31","current":14.516162,"twenty":-176.767611,"median":81.532476,"eighty":260.944352,"marketCap":3023774530},{"date":"2026-08-07","current":14.794201,"twenty":-176.56606,"median":80.513209,"eighty":260.8379,"marketCap":3081691310},{"date":"2026-08-14","current":5.765224,"twenty":-176.069381,"median":21.824041,"eighty":260.742094,"marketCap":3087300300},{"date":"2026-08-21","current":5.739385,"twenty":-175.867829,"median":21.55845,"eighty":260.635642,"marketCap":3073463660},{"date":"2026-08-28","current":5.731311,"twenty":-175.579899,"median":21.315684,"eighty":260.358869,"marketCap":3069139710},{"date":"2026-09-04","current":6.254541,"twenty":-175.112012,"median":21.259662,"eighty":260.252418,"marketCap":3349331670},{"date":"2026-09-11","current":6.144727,"twenty":-174.161842,"median":21.222313,"eighty":260.167256,"marketCap":3290525950},{"date":"2026-09-16","current":6.141497,"twenty":-174.118653,"median":21.131016,"eighty":259.752096,"marketCap":3288796370}],"updateTime":1789657495234},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"AD\",pageSize:20,pageCount:9,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2626159983","title":"Lynk Pharmaceuticals Announces NDA Acceptance for Zemprocitinib by NMPA","url":"https://stock-news.laohu8.com/highlight/detail?id=2626159983","media":"prnewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626159983?lang=en_us&edition=fundamental","pubTime":"2026-04-10 08:00","pubTimestamp":1775779200,"startTime":"0","endTime":"0","summary":"SHANGHAI, HANGZHOU, China and BOSTON, April 10, 2026 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. , a clinical-stage innovative drug development company focused on therapies for immune and inflammatory diseases, today announced that the New Drug Application  for its core product, zemprocitinib capsules, for the treatment of moderate-to-severe atopic dermatitis , has been formally accepted by the Center for Drug Evaluation  of the China National Medical Products Administration . This acceptance marks a critical milestone in the company's clinical development in inflammatory skin diseases and represents an important step toward Lynk Pharmaceuticals' transition to commercialization. Zemprocitinib capsules have the potential to provide a new treatment option for patients with atopic dermatitis.Preclinical and clinical studies have demonstrated that zemprocitinib potently and dose-dependently inhibits multiple JAK1-mediated inflammatory signaling pathways, supporting its therapeutic poten","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/lynk-pharmaceuticals-announces-nda-acceptance-for-zemprocitinib-by-nmpa-302738518.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AD","LU1223082519.USD","BK7050","AS","BK4202","CDE.AU","BK4099","CDE","LU1223082196.USD","LU1223083913.SGD","BK4132","ZK","RA","BK4017"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626874261","title":"Annovis Announces $10 Million Underwritten Offering of Common Stock and Accompanying Warrants","url":"https://stock-news.laohu8.com/highlight/detail?id=2626874261","media":"GlobeNewswire","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626874261?lang=en_us&edition=fundamental","pubTime":"2026-04-09 20:30","pubTimestamp":1775737800,"startTime":"0","endTime":"0","summary":"MALVERN, Pa., April  09, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therap","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/09/3270958/0/en/Annovis-Announces-10-Million-Underwritten-Offering-of-Common-Stock-and-Accompanying-Warrants.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AD","BK4132","LU1169589451.USD","BK4023","LU1169590202.USD","BK4139","ANVS","PD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626923789","title":"TDS publishes 2025 annual report after UScellular wireless sale to T-Mobile","url":"https://stock-news.laohu8.com/highlight/detail?id=2626923789","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626923789?lang=en_us&edition=fundamental","pubTime":"2026-04-09 00:16","pubTimestamp":1775665016,"startTime":"0","endTime":"0","summary":"TDS annual report for 2025 detailed a strategic reset following sale of UScellular wireless business and certain spectrum assets to T-Mobile, shifting focus to fiber broadband at TDS Telecom and tower leasing at Array Digital Infrastructure.Transaction closed Aug. 1, 2025 with final proceeds of USD 4.3 billion; Array issued a USD 23 per-share special dividend.TDS Telecom highlighted accelerated fiber buildout, topping 1 million marketable fiber addresses in September; long-term target raised to 2.1 million fiber service addresses.Array reported early progress as standalone tower company with more than 4,400 towers; T-Mobile signed a 15-year master lease covering 2,015 new tower sites.Management changes included Ken Dixon joining TDS Telecom in June; Anthony Carlson appointed to lead Array in November.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated c","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260408:nNDL13wNtL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4561","LU0029864427.USD","LU2264538146.SGD","BK4515","AD","LU1621768115.EUR","LU0208291251.USD","LU1267930573.SGD","LU2361045086.USD","BK4588","LU0128525929.USD","BK4585","LU1988902786.USD","LU1064131342.USD","LU1066051811.HKD","LU2384288077.EUR","LU2098885051.SGD","BK4533","IE00BMPRXN33.USD","LU1066051498.USD","LU1066051225.USD","LU1303367103.USD","LU0320765489.SGD","LU1035773651.USD","LU0267386448.USD","LU2361044949.HKD","LU0170899867.USD","LU1621767737.EUR","LU1983260115.SGD","BK4549","LU0276348264.USD","TMUS","IE00B775SV38.USD","LU2210149790.SGD","TDS","LU0640476718.USD","LU0127658192.USD","LU0251131958.USD","LU0077335932.USD","LU1621767810.EUR","LU2361044865.SGD","LU0642271901.SGD","LU2317271919.USD","IE00B3S45H60.SGD","IE00BMPRXQ63.HKD","LU0048573561.USD","LU0708994859.HKD","LU0314106906.USD","LU1280957306.USD","LU1621768206.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625911242","title":"Digitus Group Signs Agreement To Acquire Gulfsat Kuwait","url":"https://stock-news.laohu8.com/highlight/detail?id=2625911242","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625911242?lang=en_us&edition=fundamental","pubTime":"2026-04-08 17:01","pubTimestamp":1775638860,"startTime":"0","endTime":"0","summary":"April 8 (Reuters) - DIGITUS GROUP FOR DIGITAL INFRASTRUCTURE, DATA CENTERS & COMMUNICATIONS ::*DIGITUS GROUP - SIGNS AGREEMENT TO ACQUIRE GULFSAT KUWAIT*DIGITUS GROUP - TOTAL DEAL VALUE KD 6 MILLION*F","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260408:nRSD1NjBg9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AD","TDS","BK4132"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625592489","title":"Array Digital Infrastructure announces annual shareholder meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2625592489","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625592489?lang=en_us&edition=fundamental","pubTime":"2026-04-07 22:35","pubTimestamp":1775572505,"startTime":"0","endTime":"0","summary":"Array Digital Infrastructure schedules annual shareholder meeting in Chicago on May 19, 2026.Shareholders will vote on election of nine directors, including three nominees elected by common shareholders.Meeting agenda also includes charter amendment to add officer exculpation provisions.Shareholders will cast advisory vote on 2025 executive compensation.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Array Digital Infrastructure Inc. published the original content used to generate this news brief on April 07, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260407:nNDL3NDW7F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TDS","AD","BK4132"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625959242","title":"Array Digital Infrastructure publishes 2025 annual report after wireless divestiture transition","url":"https://stock-news.laohu8.com/highlight/detail?id=2625959242","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625959242?lang=en_us&edition=fundamental","pubTime":"2026-04-07 22:34","pubTimestamp":1775572497,"startTime":"0","endTime":"0","summary":"Array annual report for fiscal 2025 highlighted shift from UScellular wireless carrier to tower company, following divestiture of wireless operations to T-Mobile on Aug. 1, 2025.Company positioned as fifth-largest US tower operator, supported by more than 4,400 towers, retained wireless spectrum, noncontrolling investment interests.T-Mobile anchor deal set 15-year master lease covering 2,015 new tower sites, extending terms on about 600 existing sites.Sales and intake operations moved in-house, driving 47% rise in colocation applications, excluding impact of T-Mobile master lease.Spectrum monetization advanced with agreements covering 70% of holdings, including USD 4.3 billion transaction with T-Mobile in August 2025; remaining 30% largely C-Band spectrum.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260407:nNDL4WWGJK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AD","BK4533","LU0077335932.USD","LU0070302665.USD","LU1069347547.HKD","GB00BDT5M118.USD","LU1066051498.USD","LU1506573853.SGD","LU1621767810.EUR","LU1983260115.SGD","BK4561","LU0310800379.SGD","LU0314106906.USD","LU0276348264.USD","LU0320765489.SGD","LU2095319765.USD","LU0640476718.USD","LU0708994859.HKD","LU0061474705.USD","LU2361044865.SGD","LU0048573561.USD","LU1621768115.EUR","LU0128525929.USD","LU0267386448.USD","LU0029864427.USD","IE00BMPRXR70.SGD","LU1621768206.USD","LU1316542783.SGD","LU1303367103.USD","LU2361044949.HKD","LU1064131342.USD","LU1988902786.USD","LU1621767737.EUR","BK4549","BK4559","BK4588","LU0208291251.USD","LU1066051225.USD","LU0786609619.USD","LU2361045086.USD","IE00B775SV38.USD","LU2317271919.USD","LU2098885051.SGD","LU1267930573.SGD","LU0742534661.SGD","LU2210150020.SGD","TMUS","IE00BMPRXN33.USD","IE00BMPRXQ63.HKD","TDS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625328769","title":"Press Release: AC Immune Announces Amendment to Morphomer (R) Tau License and Collaboration Agreement with Lilly","url":"https://stock-news.laohu8.com/highlight/detail?id=2625328769","media":"Dow Jones","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625328769?lang=en_us&edition=fundamental","pubTime":"2026-04-07 19:00","pubTimestamp":1775559600,"startTime":"0","endTime":"0","summary":"-- Amended agreement reflects growing excitement in the field for targeting. intracellular Tau and significant progress made with our Morphomer small. -- Investigational New Drug -enabling studies to commence in H1 2026. Dr. Andrea Pfeifer, CEO of AC Immune SA, commented: \"The progress in this collaboration highlights the important breakthroughs we have made with Morphomer small molecules for intracellular targeting of Tau. We look forward to working with the team at Lilly to drive forward the development of these potentially disruptive small molecule therapeutics for early-stage treatment and long-term prevention of neurodegenerative diseases. Increasingly, the scientific evidence suggests that targeting intracellular Tau can slow or even completely halt the pathology. This collaboration exemplifies our work towards precision prevention of neurodegenerative diseases. We expect to initiate Investigational New Drug -enabling studies imminently.\". AC Immune SA is a clinical-stage biophar","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4022","AD","BK4139","BK4132","ACIU","R","BK4232","IND"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624753639","title":"RBC Capital Keeps Their Buy Rating on Array Digital Infrastructure (AD)","url":"https://stock-news.laohu8.com/highlight/detail?id=2624753639","media":"TIPRANKS","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624753639?lang=en_us&edition=fundamental","pubTime":"2026-04-03 09:47","pubTimestamp":1775180876,"startTime":"0","endTime":"0","summary":"RBC Capital analyst Jonathan Atkin maintained a Buy rating on Array Digital Infrastructure on April 1 and set a price target of $54.00. The company...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/rbc-capital-keeps-their-buy-rating-on-array-digital-infrastructure-ad-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/rbc-capital-keeps-their-buy-rating-on-array-digital-infrastructure-ad-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624260555","title":"Blockchain Digital Infrastructure FY25 net loss narrows to $0.8 million; revenue falls 19% to $19 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2624260555","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624260555?lang=en_us&edition=fundamental","pubTime":"2026-04-01 05:47","pubTimestamp":1774993671,"startTime":"0","endTime":"0","summary":"Blockchain Digital Infrastructure posted a net loss of USD 0.8 million for fiscal 2025.Revenue fell 19% to USD 19 million on a shift in customer mix and standstill agreements that capped energy usage and curtailed credits.Adjusted EBITDA slid 74% to USD 1.7 million.Cash from operations dropped to USD 2.3 million, leaving cash at USD 15,265 at year-end.Company expects One Blockchain South Carolina facility to expand from 40 MW to 50 MW, pending a new electric service agreement, and is developing a 25 MW AI-focused Minnesota site.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Blockchain Digital Infrastructure Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retr","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260331:nNDL4VFLrM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TDS","BK4132","BK4023","AIB","AD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624676537","title":"Press Release: Connect Biopharma Reports 2025 Full-Year Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2624676537","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624676537?lang=en_us&edition=fundamental","pubTime":"2026-04-01 04:05","pubTimestamp":1774987500,"startTime":"0","endTime":"0","summary":"-- Released positive topline data from Phase 1 study of IV rademikibart in patients with asthma or COPD --. -- Results from Phase 3 study of rademikibart in moderate-to-severe AD presented in late-breaking research session at AAD --. -- Recruitment ongoing for Phase 2 Seabreeze STAT studies for acute exacerbations in asthma and COPD; expect to report topline data from both studies mid-2026 --. -- Entered into a securities purchase agreement for $20.2 million equity financing extending our cash runway into second half of 2027 --. SAN DIEGO, March 31, 2026  -- Connect Biopharma Holdings Limited  , a clinical-stage biopharmaceutical company focused on transforming care for the treatment of inflammatory diseases, today reported financial results for the three and twelve months ended December 31, 2025, and provided a business update.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AD","BK4139","CNTB","BK4132"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623584887","title":"Annovis Publishes Historical Review of Buntanetap in The Scientist","url":"https://stock-news.laohu8.com/highlight/detail?id=2623584887","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623584887?lang=en_us&edition=fundamental","pubTime":"2026-03-31 20:00","pubTimestamp":1774958400,"startTime":"0","endTime":"0","summary":"MALVERN, Pa., March  31, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therap","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/31/3265424/0/en/Annovis-Publishes-Historical-Review-of-Buntanetap-in-The-Scientist.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ANVS","LU1169589451.USD","BK4132","BK4139","AD","BK4023","PD","LU1169590202.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623206803","title":"Should Apogee Therapeutics’ (APGE) Infrequent-Dosing AD Data and $403M Equity Raise Require Investor Action?","url":"https://stock-news.laohu8.com/highlight/detail?id=2623206803","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623206803?lang=en_us&edition=fundamental","pubTime":"2026-03-31 06:09","pubTimestamp":1774908562,"startTime":"0","endTime":"0","summary":"Apogee Therapeutics recently reported positive 52-week Phase 2 APEX trial data for its lead anti-IL-13 antibody zumilokibart in moderate-to-severe atopic dermatitis, alongside completing a follow-on common stock offering of about US$403,000,000 at US$70 per share.\nThe maintenance data suggest zumilokibart may offer durable disease control with 3- or 6-month dosing intervals, a dosing schedule that could meaningfully differentiate it from existing atopic dermatitis treatments if later-stage...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-apge/apogee-therapeutics/news/should-apogee-therapeutics-apge-infrequent-dosing-ad-data-an","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-apge/apogee-therapeutics/news/should-apogee-therapeutics-apge-infrequent-dosing-ad-data-an","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","APGE","BK4585","LU0053671581.USD","BK4215","EQR","AD","BK4132","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623432640","title":"Press Release: INmune Bio Inc. Announces 2025 Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2623432640","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623432640?lang=en_us&edition=fundamental","pubTime":"2026-03-31 04:00","pubTimestamp":1774900800,"startTime":"0","endTime":"0","summary":"BOCA RATON, Fla., March 30, 2026  -- INmune Bio Inc.  , a late-stage biotechnology company focused on inflammation and immunology, today announces its financial results for the year ended December 31, 2025 and provides a business update.-- The CORDStrom program in recessive dystrophic epidermolysis bullosa.  is on target to file an MAA submission in the UK mid-summer,followed shortly thereafter by anticipated EMA and FDA regulatory. -- Hosted KOL led webinar focused on the latest results from the MissionEB. Phase III clinical trial highlighting the systemic disease-modifying. -- Announced the publishing of an overview of future applications and. research areas for mesenchymal stromal cell  therapies in the. -- Reported new Phase 2 imaging data at the 18th Clinical Trials on. Alzheimer's Disease conference , in San Diego, CA. Additional brain. imaging analyses are ongoing and expected to be reported in the near. -- Announced FDA alignment to advance to an adaptive Phase 2b/3. early Alzh","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4232","MSC","BK4215","R","BK4588","INMB","BK4150","TM","BK4099","BK4022","BK4132","AD","BK4139","03160","BK4604","BK4555","BK4575","BK4585","MAA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623114593","title":"Rademikibart Demonstrates Best-in-Class Potential in Phase 3 Atopic Dermatitis Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2623114593","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623114593?lang=en_us&edition=fundamental","pubTime":"2026-03-30 19:01","pubTimestamp":1774868460,"startTime":"0","endTime":"0","summary":"– Rademikibart achieved rapid, durable efficacy results across all key endpoints through 52 weeks, with nearmaximal responses achieved in ~90% of patients – –Rademikibart was well tolerated with safet","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/30/3264498/0/en/Rademikibart-Demonstrates-Best-in-Class-Potential-in-Phase-3-Atopic-Dermatitis-Study.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4132","AD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623731901","title":"Press Release: Neumora Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2623731901","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623731901?lang=en_us&edition=fundamental","pubTime":"2026-03-30 18:53","pubTimestamp":1774867980,"startTime":"0","endTime":"0","summary":"New data for NMRA-511 supports unsurpassed clinical effect in a pre-specified population comparable to Rexulti and Auvelity pivotal studies. KOASTAL-2 and -3 fully enrolled in the first quarter of 2026; on track for topline readout in the second quarter of 2026. NMRA-898 selected as lead program in M4 franchise based on promising clinical results from ongoing Phase 1 study. \"We saw significant progress in 2025, laying the foundation for a catalyst-rich year ahead as we advance our pipeline of next-generation therapies for people living with brain diseases,\" said Paul L. Berns, co-founder, chairman and chief executive officer of Neumora. \"In the first quarter of 2026, we confirmed next steps for navacaprant and our M4 franchise, as well as generated compelling results supporting the potential unsurpassed profile of NMRA-511 in Alzheimer's disease agitation, which we built upon today with the announcement of additional data from a pre-specified analysis.\"","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4081","BK4132","PAM","NMRA","BK4007","AD","BK4563"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623354697","title":"Nektar announces data from Phase 2b Rezolve-AD, Rezolve-AA studies","url":"https://stock-news.laohu8.com/highlight/detail?id=2623354697","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623354697?lang=en_us&edition=fundamental","pubTime":"2026-03-29 23:40","pubTimestamp":1774798807,"startTime":"0","endTime":"0","summary":"Nektar (NKTR) Therapeutics showcased data in two presentations at the 2026 American Academy of Dermatology, AAD, Annual Meeting taking place in Den...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/nektar-announces-data-from-phase-2b-rezolve-ad-rezolve-aa-studies-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/nektar-announces-data-from-phase-2b-rezolve-ad-rezolve-aa-studies-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU2543165471.USD","BK4585","AA","BK4153","BK4588","NKTR","BK4132","BK4007","AD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1145791023","title":"Wahaha Temporarily Halts Majority of Production Lines, Including AD Calcium Milk and Nutri-Express","url":"https://stock-news.laohu8.com/highlight/detail?id=1145791023","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1145791023?lang=en_us&edition=fundamental","pubTime":"2026-03-28 16:10","pubTimestamp":1774685429,"startTime":"0","endTime":"0","summary":"On March 27, reports emerged indicating that Wahaha had issued an urgent notice the previous day to suspend approximately 70% of its factory production lines. The temporary halt affected multiple...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4132","AD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622878067","title":"Celldex Presents Positive Data from Phase 2 Chronic Spontaneous Urticaria and Phase 2 Cold Urticaria and Symptomatic Dermographism Studies Demonstrating Rapid, Profound and Durable Improvements in Patient Quality of Life at AAD 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2622878067","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622878067?lang=en_us&edition=fundamental","pubTime":"2026-03-27 22:30","pubTimestamp":1774621800,"startTime":"0","endTime":"0","summary":"- Improvements seen across all six DLQI Domains indicating broad, beneficial impact on quality of life -- Data further demonstrates first-in-class and best-in-disease barzolvolimab profile - HAMPTON, ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/27/3263841/24180/en/Celldex-Presents-Positive-Data-from-Phase-2-Chronic-Spontaneous-Urticaria-and-Phase-2-Cold-Urticaria-and-Symptomatic-Dermographism-Studies-Demonstrating-Rapid-Profound-and-Durable-.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PN","BK4132","BK4213","SD","CLDX","BK4139","AD","BK4096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622820127","title":"Results Presented at 2026 American Academy of Dermatology (AAD) Annual Meeting Provide Additional Support for the Therapeutic Potential of ATI-2138","url":"https://stock-news.laohu8.com/highlight/detail?id=2622820127","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622820127?lang=en_us&edition=fundamental","pubTime":"2026-03-27 22:10","pubTimestamp":1774620600,"startTime":"0","endTime":"0","summary":"- Participants with Atopic Dermatitis Receiving ATI-2138 Experienced Improvements in Key Clinical Measures including Disease Severity, Itch, and Quality of Life - WAYNE, Pa., March  27, 2026 (GLOBE NE","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/27/3263826/37216/en/Results-Presented-at-2026-American-Academy-of-Dermatology-AAD-Annual-Meeting-Provide-Additional-Support-for-the-Therapeutic-Potential-of-ATI-2138.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACRS","EASI","LU0963586101.USD","BK4117","BK4007","IE00B19Z4B17.USD","BK4107","ATI","IE00B66KJ199.SGD","AFG","IE00B7SZL793.SGD","BK4132","LU1878469433.USD","BK4187","LU2065731478.USD","BK4006","IE0031619046.USD","BSA","AD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622482558","title":"GMO AD Partners Details Governance Ties to Controlling Shareholder GMO Internet Group","url":"https://stock-news.laohu8.com/highlight/detail?id=2622482558","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622482558?lang=en_us&edition=fundamental","pubTime":"2026-03-27 14:57","pubTimestamp":1774594678,"startTime":"0","endTime":"0","summary":"The latest update is out from GMO AD Partners Inc. ( ($JP:4784) ). GMO AD Partners Inc., a key subsidiary in the GMO Internet Group, is positioned ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/gmo-ad-partners-details-governance-ties-to-controlling-shareholder-gmo-internet-group?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/gmo-ad-partners-details-governance-ties-to-controlling-shareholder-gmo-internet-group?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4132","GMO","AD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":9,"totalSize":187,"code":"91000000","status":"200"}]}}